2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Palliative Care, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Bacterial, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3380 Venetoclax plus decitabine, cytarabine, aclarubicin, and G-CSF mitigates the adverse impact of monocytic differentiation in newly diagnosed acute myeloid leukemia

Kun Yang, Jin Rao, MD2, Xu He3, Hongbin Ma4, Yuping Gong Sr, MD5
1 West China Hospital, Sichuan University, Chengdu, Sichuan, China
2 Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, China
3 Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region, Chengdu, China
4 West China Hospital, Sichuan University, Chengdu, China
5 West China Hospital, Sichuan University, Chengdu, Sichuan, China
Background
Monocytic differentiation has been associated with poor outcomes following venetoclax plus hypomethylating agents in acute myeloid leukemia (AML). Whether this adverse therapeutic impact persists with venetoclax plus decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (VD-CAG) remains unclear. We evaluated the efficacy of frontline VD-CAG according to monocytic differentiation and explored the biological mechanisms underlying its activity in monocytic AML. 
Methods
In this multicenter retrospective study, 188 patients with newly diagnosed AML who received frontline VD-CAG were enrolled. Patients were classified by FAB morphology and flow cytometric immunophenotyping, and treatment outcomes were evaluated using both approaches. Treatment responses and survival outcomes were compared between patients with different characteristics. Exploratory transcriptomic analyses and in vitro functional studies were conducted to investigate the mechanisms of the venetoclax, decitabine, cytarabine, and aclarubicin (VDCA) combination in monocytic-like AML cells. 
Results
Among the 188 patients, 80 (42.6%) had FAB M4/M5 AML. After the first induction cycle, the composite complete remission (CRc) rate was 86.7% (95% CI, 81.0%–91.2%), with 67.6% (95% CI, 60.4%–74.2%) achieving measurable residual disease negativity. CRc rates were comparable between M4/M5 and non-M4/M5 AML patients (86.3% vs. 87.0%; P=0.875) and remained similar across ELN 2022 risk groups, age categories, and major molecular subgroups. After a median follow-up of 22.9 months, the estimated 12-month overall survival and event-free survival rates were 81% (95% CI, 74%–86%) and 64% (95% CI, 56%–70%), respectively. Neither FAB-defined monocytic differentiation nor a flow cytometry-defined monocytic-like phenotype independently predicted remission, overall survival, or event-free survival. Mechanistically, VDCA disrupted key monocytic differentiation–associated survival programs in monocytic-like AML cells through suppression of MAPK/ERK signalling, downregulation of MCL-1 and BCL-XL expression, increased apoptosis, and impaired mitochondrial respiration. Together, the comparable clinical outcomes across differentiation phenotypes, supported by these mechanistic findings, suggest that VD-CAG may attenuate the adverse therapeutic impact of monocytic differentiation in AML.
Conclusions
Frontline VD-CAG achieved high remission rates and encouraging survival in newly diagnosed AML regardless of monocytic differentiation status. Monocytic differentiation was not independently associated with treatment response or survival, suggesting that its adverse therapeutic impact may be attenuated by chemotherapy-containing venetoclax-based regimens. These clinical and mechanistic findings support further prospective evaluation of VD-CAG as a therapeutic strategy for patients with monocytic AML.
Kun Yang: No relevant conflicts of interest to declare.